Bionomics receives huge R&D tax refund
Biopharmaceutical developer Bionomics (ASX: BNO) has received a $5.2 million R&D Tax Incentive Refund for 2018/2019 recognising its intense product development efforts. The company, which is developing a number of novel drug candidates based its unique ionX platform technology, appears to have received one of the largest refunds for the year. While most young drug…











